Catalyst Pharma 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors.

.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a great run on the share market with its stock up by a significant 11. 1%, compared to the Zacks S&P 500 composite's +9% change.

.

40% lower than it was a year ago.

The S&P 500 dropped 1. 10. 2%.

.

CATALYST PHARMACEUTICALS, INC. . .

Catalyst Pharmaceuticals "hit the ball out of the park" in the first quarter, says Chief Executive Patrick McEnany. Feb 3, 2023 · Catalyst is expected to post earnings of $0.

They are listed on the NASDAQ.

10% in the past year, while Johnson & Johnson (JNJ) has traded -0.

. com - May 11 at 10:26 AM: Catalyst Pharmaceuticals Inc.

closed $10. S.

Why Acadia Pharma Surged Despite A Negative FDA Take On Its Lead Drug;.
The S&P 500 dropped 1.
The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

75.

97% lower than its previous close.

61. 10% in the past year, while Johnson & Johnson (JNJ) has traded -0. 10 a year ago.

. . . Given the company's impressive performance, we. .

.

. 2 days ago · Stocks fell Tuesday as ongoing debt ceiling discussions appeared to yield little progress.

36 below its 52-week high ($22.

20 per share for the current quarter, representing a year-over-year change of +122.

00.

00.

.